Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer

Conclusion: 203Pb-L1–203Pb-L5 demonstrated favorable pharmacokinetics for 212Pb-based TRT. The antitumor efficacy of 212Pb-L2 supports the corresponding 203Pb/212Pb theranostic pair for PSMA-based α-particle TRT in advanced PC.

Source: Journal of Nuclear Medicine - January 1, 2020 Category: Nuclear Medicine Authors: Banerjee, S. R., Minn, I., Kumar, V., Josefsson, A., Lisok, A., Brummet, M., Chen, J., Kiess, A. P., Baidoo, K., Brayton, C., Mease, R. C., Brechbiel, M., Sgouros, G., Hobbs, R. F., Pomper, M. G. Tags: Basic Source Type: research